Prothena Corp plc Stock: Clinical Milestones and Strategic Focus in Biotechnology Drive Investor Int
Prothena Corp plc (PRTA) is gaining investor interest due to its advancements in neurodegenerative disease treatments, particularly for conditions like Alzheimer's and Parkinson's. The company leverages proprietary technologies and strategic partnerships with major pharmaceutical companies like Roche and Novo Nordisk. Key pipeline candidates like birtamimab for AL amyloidosis and coramitug for neurodegenerative conditions are progressing through late-stage clinical trials, attracting North American investors seeking biotech exposure.
PRTA Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Prothena Corporation PLC (PRTA). It highlights a "Strong Buy" technical sentiment based on various indicators, including moving averages and momentum oscillators. Key support and resistance levels are identified, along with an assessment of the stock's performance relative to its moving averages and RSI status.
Prothena Corp plc Stock: Clinical Milestones and Strategic Focus in Biotechnology Drive Investor Int
Prothena Corp plc, a NASDAQ-listed biotech firm, is gaining investor interest due to its advancements in neurodegenerative disease treatments, strategic partnerships, and clinical milestones. The company focuses on protein misfolding disorders, leveraging proprietary technologies and collaborations with major players like Roche and Novo Nordisk. Progress in its pipeline, including birtamimab for AL amyloidosis and coramitug for neurodegenerative conditions, demonstrates its potential for high returns for North American investors while acknowledging inherent risks in biotech investing.
PRTA Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for PRTA, highlighting past quarterly results and future forecasts. It details revenue and EPS estimates for upcoming quarters, analyst revisions, and the historical stock price reactions around earnings reports. The piece also includes a summary of the sentiment from Prothena Corporation PLC's Q4 2025 earnings call, indicating mixed feelings among investors.
Understanding Momentum Shifts in (PRTA)
This article analyzes Prothena Corporation Plc (PRTA) using AI models, identifying a near-term strong sentiment transitioning to mid-term neutrality and long-term positive bias. It presents three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—alongside multi-timeframe signal analysis for support and resistance levels. The analysis highlights a significant 56.7:1 risk-reward short setup, signaling potential downside.
JPMorgan Chase & Co. Buys 608,814 Shares of Prothena Corporation plc $PRTA
JPMorgan Chase & Co. significantly increased its stake in Prothena Corporation plc, purchasing an additional 608,814 shares, bringing its total holding to 735,765 shares valued at approximately $7.18 million. Despite this institutional interest, Prothena remains unprofitable, reporting an EPS of -$0.44 against significantly lower-than-expected revenue. Analyst ratings for the biotechnology company are mixed, with a consensus "Hold" rating and a target price of $21.67.
When Can We Expect A Profit From Prothena Corporation plc (NASDAQ:PRTA)?
Prothena Corporation plc, a late-stage clinical biotechnology company, is anticipated to reach profitability by 2028, according to industry analysts. The company is expected to incur a final loss in 2027 before generating positive profits of US$1.4 million in 2028, requiring an aggressive annual growth rate of 80%. A notable aspect of Prothena's financial position is its debt-free balance sheet, which is uncommon for a loss-making biotech company and reduces investment risk.
Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by Analysts
MarketBeat reports that Prothena Corporation plc (NASDAQ:PRTA) has received a consensus "Hold" rating from eleven analysts, with an average 1-year price target of $21.67. Institutions own 97.08% of the stock, and the company recently reported a slight EPS beat despite being unprofitable, with very negative net margins and return on equity. Prothena is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and rare diseases.
Wall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a Bet
Wall Street analysts project a potential 120.19% surge for Prothena (PRTA), with a mean price target of $20.5 despite a significant standard deviation in estimates. While impressive price targets often mislead, analysts' increasing optimism about the company's earnings and a Zacks Rank #2 (Buy) suggest a potential upside. Investors are advised to use price targets as a starting point for further research, exercising skepticism due to potential biases.
Prothena (NASDAQ:PRTA) Shares Cross Below Two Hundred Day Moving Average - Here's What Happened
Prothena (NASDAQ:PRTA) shares have fallen below their 200-day moving average, trading as low as $8.76 on Monday with a 200-day moving average of $9.56. Analysts have a consensus "Hold" rating for the stock with an average target price of $21.67, and the company recently reported quarterly earnings that beat consensus estimates. Institutional investors and hedge funds own a significant portion of the company's stock, with several making recent adjustments to their holdings.
Prothena Corp plc stock gains spotlight as partners Roche and Bristol-Myers Squibb showcase key clin
Prothena Corp plc is gaining increased investor attention after its partners, Roche and Bristol-Myers Squibb, presented promising clinical data for prasinezumab (Parkinson's) and BMS-986446 (Alzheimer's) at the AD/PD 2026 conference. This highlights Prothena's advancing pipeline in neurodegenerative diseases, driven by strategic partnerships that de-risk development and provide a diversified asset base. The company's partnership model and pipeline progress make it an attractive consideration for DACH investors seeking defensive growth in the biotech sector.
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
Prothena Corporation plc announced that its partners, Roche and Bristol Myers Squibb, presented clinical updates on investigational treatments for Parkinson’s and Alzheimer’s diseases at the AD/PD™ 2026 conference. Roche presented data on prasinezumab, suggesting potential disease-modifying efficacy and sustained effects in slowing Parkinson's progression. Bristol Myers Squibb shared safety and pharmacokinetic data for BMS-986446, a potential Alzheimer's treatment, showing it was well-tolerated.
Prothena Corp plc stock faces pressure amid biotech volatility and pipeline updates
Prothena Corp plc's stock is experiencing pressure due to biotech market volatility and ongoing pipeline developments, with shares trading around $10.39 on NASDAQ. The company, focused on protein misfolding diseases, is advancing key candidates like birtamimab for AL amyloidosis and collaborating on ATTR amyloidosis therapies. Despite analyst 'Hold' ratings and financial challenges common to development-stage biotechs, successful clinical readouts in its amyloidosis pipeline could offer significant upside, appealing to investors in the neurodegeneration sector.
Avoiding Lag: Real-Time Signals in (PRTA) Movement
This article provides a real-time analysis of Prothena Corporation Plc (NASDAQ: PRTA), highlighting weak near-term sentiment despite long-term strength. It details an exceptional 65.7:1 risk-reward short setup and outlines specific institutional trading strategies, including long, momentum breakout, and risk hedging options based on AI-generated signals for different time horizons. The analysis emphasizes real-time entry and exit signals, risk-reward ratios, and multi-timeframe updates for traders.
Prothena Corp plc Stock (ISIN: IE00B91XRN20) Faces Biotech Headwinds Amid Pipeline Delays
Prothena Corp plc (ISIN: IE00B91XRN20) stock is under pressure due to competitive dynamics in the neurodegeneration sector and a lack of fresh catalysts for its Alzheimer's and ALS candidates. Despite a strong balance sheet with over $800 million in cash, allowing operations into 2028, investor caution is evident over clinical timelines and funding needs. The company's lead asset, prasinezumab, is in Phase 2/3 trials, with data expected in late 2026, while competitors advance their own technologies.
Prothena Corp plc Stock (ISIN: IE00B91XRN20) Faces Biotech Headwinds Amid Pipeline Delays
Prothena Corp plc (ISIN: IE00B91XRN20) is experiencing stock pressure due to investor caution over clinical trial timelines and funding needs in the highly competitive neurodegeneration sector. Despite a strong balance sheet and cash runway into 2028, the lack of recent data catalysts, especially concerning its Alzheimer's and ALS candidates, leaves it vulnerable amidst active fundraising by peers. The company's future hinges on upcoming data readouts for its lead assets, prasinezumab and Birketvedt, in late 2026 and 2027, respectively.
Prothena Corp plc Stock (ISIN: IE00B91XRN20) Faces Headwinds Amid Biotech Volatility
Prothena Corp plc (ISIN: IE00B91XRN20), a clinical-stage biotech focusing on amyloid diseases, is experiencing volatile trading due to broader biotech sector pressures and mixed technical signals. Key developments include a collaborative advancement of an ATTR amyloidosis drug into Phase 3 and FDA clearance for another amyloid-targeting therapy. The company faces financial challenges common to pre-commercial biotechs, with analysts holding a "Hold" consensus amidst tempered expectations but acknowledging significant pipeline potential.
Prothena Corp plc Stock (ISIN: IE00B91XRN20) Under Pressure Amid Biotech Volatility
Prothena Corp plc (ISIN: IE00B91XRN20) stock is experiencing downward pressure, falling over 2% amidst broader biotech sector volatility. Despite analyst optimism and a $19 price target from Citizens JMP, the clinical-stage biotech faces challenges but holds promise with its NEODX platform and pipeline, including a Phase 3 asset for AL amyloidosis. European investors are monitoring its Xetra listing and partnerships with firms like Roche.
Prothena earns $50M milestone from Novo Nordisk for drug trial
Prothena Corporation plc received a $50 million milestone payment from Novo Nordisk for achieving a prespecified enrollment target in the Phase 3 CLEOPATTRA clinical trial evaluating coramitug for ATTR amyloidosis. This payment brings Prothena's total milestone earnings from its agreement with Novo Nordisk to $150 million, with potential for up to $1.2 billion. The company also recently authorized a $100 million share repurchase program and holds a strong cash position.
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
Prothena Corporation plc announced it achieved a $50 million clinical milestone payment from Novo Nordisk. This payment is linked to the ongoing Phase 3 clinical trial of coramitug (formerly PRX004), an investigational antibody, in patients with ATTR amyloidosis with cardiomyopathy. The milestone underscores progress in their collaboration to develop treatments for this debilitating disease.
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
Prothena has announced it received a $50 million clinical milestone payment from Novo Nordisk for achieving a prespecified enrollment target in the Phase 3 CLEOPATTRA clinical trial for coramitug. This payment contributes to the $150 million Prothena has earned to date out of a potential $1.2 billion in milestones from Novo Nordisk for coramitug, a potential first-in-class amyloid depleter antibody for ATTR amyloidosis with cardiomyopathy. The trial, with an expected primary completion in 2029, evaluates coramitug's efficacy in approximately 1280 participants.
Discipline and Rules-Based Execution in PRTA Response
Quantitative Research Desk has provided an analysis for Prothena Corporation Plc (NASDAQ: PRTA), highlighting that if the current strong near and mid-term sentiment persists, it could extend into the long term. The analysis identifies a mid-channel oscillation pattern and an exceptional 77.7:1 risk-reward setup, targeting a 24.6% gain against a 0.3% risk. Three distinct AI-generated trading strategies are offered for different risk profiles: Position Trading, Momentum Breakout, and Risk Hedging.
Prothena earns $50M milestone from Novo Nordisk for drug trial
Prothena Corporation plc (NASDAQ:PRTA) received a $50 million milestone payment from Novo Nordisk after achieving an enrollment target in the Phase 3 CLEOPATTRA clinical trial for coramitug, an investigational antibody for ATTR amyloidosis with cardiomyopathy. This payment contributes to the $150 million Prothena has earned out of a potential $1.2 billion in milestones from Novo Nordisk. Prothena, a late-stage biotechnology company, specializes in neurodegenerative and rare peripheral amyloid diseases, and InvestingPro analysis suggests the company holds more cash than debt and is projected to be profitable this year.
Prothena earns $50M milestone from Novo Nordisk for drug trial
Prothena Corporation plc received a $50 million milestone payment from Novo Nordisk for achieving an enrollment target in the Phase 3 CLEOPATTRA clinical trial of coramitug, an investigational antibody for ATTR amyloidosis with cardiomyopathy. Prothena has now accumulated $150 million of a total $1.2 billion in potential milestone payments from Novo Nordisk, which acquired the rights to Prothena's ATTR amyloidosis program in 2021. The biotechnology company is also engaged in a share repurchase program and analysts predict profitability for the current year.
Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade
Wall Street analysts project Prothena (PRTA) stock could rally by 118.09%, with a mean price target of $20.5 despite a wide standard deviation in estimates. While such price targets can be misleading due to potential analyst optimism, a strong agreement among analysts regarding Prothena's earnings prospects and a favorable Zacks Rank #2 (Buy) offer a more reliable indicator for potential upside. Investors are advised to use price targets with skepticism but consider the positive trend in earnings estimate revisions.
Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of "Hold" by Analysts
Prothena Corporation plc (NASDAQ:PRTA) has received an average "Hold" rating from eleven brokerages, with an average 1-year price target of $22.00. The company's stock currently trades around $8.67, with recent earnings showing a slight beat on EPS but a miss on revenue. Institutional investors hold a significant majority of the shares, and some have recently increased their positions.
Prothena Announces up to $100 Million Share Repurchase Plan
Prothena Corporation plc (NASDAQ:PRTA) has announced a Share Repurchase Plan, authorized by its Board of Directors, to repurchase up to $100.0 million of its outstanding ordinary shares. The company reported $308.4 million in cash and no debt as of December 31, 2025, and anticipates ending 2026 with approximately $255 million in cash, excluding potential clinical milestone payments of up to $105 million from strategic partners. Repurchases will occur in open market transactions and the plan is set to expire on December 31, 2026.
PRTA SEC Filings - Prothena 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Prothena (PRTA) SEC filings, including 10-K, 10-Q, and 8-K forms, along with AI-powered summaries. Investors can access detailed regulatory disclosures and AI-generated highlights to understand the company's financial condition, capital structure, and operational events. Recent filings cover quarterly financial results, collaboration developments, and insider trading activities, such as the Chief Scientific Officer's share acquisition.
Prothena (NASDAQ: PRTA) reshapes pipeline and cuts staff in 10-K
Prothena (NASDAQ: PRTA) announced significant pipeline changes and a workforce reduction in its annual report. The company discontinued birtamimab development after a Phase 3 trial failure and cut approximately 63% of its staff to reduce operating costs. Prothena will now focus on its partnered programs, including prasinezumab with Roche, coramitug with Novo Nordisk, and BMS-986446 and PRX019 with Bristol Myers Squibb, which represent significant potential milestone and royalty revenues.
PRTA SEC Filings - Prothena 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Prothena Corporation plc's (NASDAQ: PRTA) SEC filings, including annual 10-K reports, quarterly 10-Q filings, 8-K material event reports, and insider trading forms. It leverages AI-powered summaries to simplify understanding of these regulatory documents. The article details recent 8-K filings concerning financial results, workforce reductions, collaboration developments, and governance matters.
Prothena Announces up to $100 Million Share Repurchase Plan
Prothena Corporation plc has announced a new Share Repurchase Plan, authorized by its Board of Directors, to repurchase up to $100 million of its outstanding ordinary shares. The company reported $308.4 million in cash, cash equivalents, and restricted cash with no debt as of December 31, 2025, and expects to end 2026 with approximately $255 million, excluding potential repurchases and up to $105 million in clinical milestone payments. This plan, which may involve open market transactions and Rule 10b5-1 plans, is set to expire on December 31, 2026.
Prothena Announces $100 Million Share Repurchase Program
Prothena has announced a share repurchase program of up to $100 million, authorized through December 31, 2026. This move is supported by the company's strong cash position of $308.4 million and no debt, alongside potential milestone payments from partners. The repurchase plan aims to enhance shareholder returns and signifies Prothena's confidence in its financial health and pipeline, focusing on neurodegenerative and amyloid diseases.
Prothena Announces up to $100 Million Share Repurchase Plan
Prothena Corporation plc has announced a Share Repurchase Plan authorized by its Board of Directors, allowing the company to repurchase up to $100 million of its outstanding ordinary shares. As of December 31, 2025, Prothena had $308.4 million in cash, cash equivalents, and restricted cash with no debt, and expects to end 2026 with approximately $255 million, excluding potential milestone payments of up to $105 million from partners. The repurchase plan, which may include open market transactions and Rule 10b5-1 plans, is set to expire on December 31, 2026.
PROTHENA CORP PUBLIC LTD CO SEC 10-K Report
Prothena Corporation plc has released its 2025 10-K report, detailing a significant decrease in total revenue to $9.7 million and a net loss of $(244.1) million, largely due to reduced collaboration revenue and increased restructuring costs. The late-stage clinical biotechnology company, focused on neurodegenerative and rare peripheral amyloid diseases, is advancing several clinical trials and collaborations while aiming to optimize operations and pursue strategic partnerships. Prothena faces substantial financial, operational, regulatory, and market risks, and will require additional capital to sustain operations beyond the next twelve months.
Prothena Corporation plc (NASDAQ: PRTA) clears shelf to sell up to $200M in shares
Prothena Corporation plc (NASDAQ: PRTA) has amended its shelf registration, allowing it to offer and issue up to $200,000,000 in ordinary shares over time. This post-effective amendment also states that Prothena will no longer qualify as a well-known seasoned issuer after filing its Annual Report for December 31, 2025. Each future offering under this shelf will be detailed in a separate prospectus supplement, specifying amounts, prices, and distribution methods.
Behavioral Patterns of PRTA and Institutional Flows
This article analyzes Prothena Corporation Plc (NASDAQ: PRTA) using AI models, highlighting weak near-term sentiment and a potential bearish setup with an exceptional 80.7:1 risk-reward short opportunity. It outlines specific trading strategies – Long Position, Momentum Breakout, and Short Risk Hedging – with entry/exit points, targets, and stop losses. The analysis suggests resistance is being tested, and if it holds, support is expected next.
Prothena Announces up to $100 Million Share Repurchase Plan
Prothena Corporation plc (NASDAQ:PRTA) has announced a Share Repurchase Plan authorized by its Board of Directors, allowing the company to repurchase up to $100.0 million of its outstanding ordinary shares. This plan expires on December 31, 2026, and the company expects to end 2026 with approximately $255 million in cash, excluding potential clinical milestone payments. Prothena, a late-stage clinical biotechnology company, aims to manage its capital allocation while advancing its pipeline of investigational therapeutics.
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena Corporation plc reported its financial results for the fourth quarter and full year 2025, detailing a net loss of $21.6 million and $244.1 million, respectively, and providing a financial guidance for 2026. The company highlighted advancements in its pipeline, including the initiation of Phase 3 clinical trials for prasinezumab and coramitug by its partners Roche and Novo Nordisk, respectively, and the progression of other partnered and proprietary programs. Prothena also discussed its cash position, expected net cash use for 2026, and the potential for a share redemption program.
RBC Capital Raises Price Target for Prothena Corp (PRTA) to $12.00 | PRTA Stock News
RBC Capital has raised its price target for Prothena Corp (PRTA) from $11.00 to $12.00, while maintaining a "Sector Perform" rating. This adjustment reflects an increase in valuation, consistent with other analyst updates for the biotechnology company. Prothena Corp focuses on developing therapeutics for neurodegenerative, rare, and peripheral amyloid diseases.
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena Corporation plc reported its financial results for the fourth quarter and full year 2025, revealing a net loss of $21.5 million and $122.3 million respectively. The company also provided 2026 financial guidance, projecting a full-year net cash used in operating and investing activities to be $50 million to $55 million. Prothena highlighted advancements in its pipeline programs, including pridopirdine for Parkinson's disease, AN002 (formerly PRX004) for ATTR amyloidosis, and PRX012 for Alzheimer's disease.
Prothena (NASDAQ:PRTA) Price Target Raised to $12.00
Royal Bank of Canada has increased its price target for Prothena (NASDAQ:PRTA) from $11.00 to $12.00, maintaining a "sector perform" rating and suggesting a potential upside of 36.92%. While analyst coverage is mixed, with an average "Hold" rating and a consensus price target of $22.00, Prothena recently reported beating EPS estimates despite minimal revenue. The company is a clinical-stage biotechnology firm focused on neurodegenerative diseases, with significant institutional ownership.
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus
Prothena reported a Q4 2025 adjusted loss per share of 45 cents, meeting estimates, and revenues of $0.02 million, missing expectations. The company provided 2026 guidance, expecting net cash burn between $50 million-$55 million and potential milestone payments of up to $105 million from partners like Novo Nordisk and Bristol Myers Squibb. Prothena also highlighted progress in its pipeline, including late-stage studies for Parkinson's and ATTR amyloidosis with cardiomyopathy.
Prothena Corporation plc (NASDAQ:PRTA) Q4 2025 Earnings Call Transcript
Prothena Corporation plc discussed their Q4 2025 financial results and provided 2026 guidance, highlighting significant progress in their clinical pipeline with two partner programs, prasinezumab and coramitug, advancing into Phase III trials. The company also introduced its CYTOPE technology for targeting intracellular disease pathways and outlined strategic priorities for 2026, including capturing value from partnerships and potential share redemption. They also discussed progress on BMS-986446 for Alzheimer's and PRX019 for neurodegenerative diseases.
Prothena (NASDAQ:PRTA) Announces Earnings Results
Prothena (NASDAQ:PRTA) has released its quarterly earnings, reporting an EPS of ($0.40), which surpassed the consensus estimate of ($0.45). Despite the EPS beat, revenue significantly declined to $0.02 million against an expected $0.67 million, and profitability metrics were deeply negative. Shares traded at $9.03 following the announcement, with analysts holding a "Hold" consensus rating and institutional investors showing significant buying activity.
Prothena Corporation plc announced that the company has the potential to receive up to $105 million in cumulative clinical milestone payments by the end of 2026.
Prothena Corporation plc announced that it could receive up to $105 million in cumulative clinical milestone payments by the end of 2026. This potential funding is contingent on the clinical progress of key projects within its research and development pipeline. The announcement highlights the company's anticipated financial gains from its ongoing R&D efforts.
Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead?
Prothena's stock has dropped 36.8% over the past year, largely due to pipeline setbacks, including the discontinuation of birtamimab in a late-stage study. The company is now focusing on earlier-stage assets and partnered programs with Novo Nordisk, Roche, and Bristol Myers Squibb. Prothena also undertook a significant workforce reduction to manage operating costs.
(PRTA) Movement Within Algorithmic Entry Frameworks
This article analyzes Prothena Corporation Plc (NASDAQ: PRTA) using algorithmic entry frameworks. It highlights strong near-term sentiment potentially challenging persistent mid and long-term weakness and identifies support being tested. The analysis suggests an exceptional 147.5:1 risk-reward setup targeting a 34.5% gain, providing specific institutional trading strategies for long and short positions, along with multi-timeframe signal analysis.
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
Prothena Corporation plc announced it will report its fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of U.S. financial markets. This will be followed by a live audio conference call at 4:30 PM ET. A replay of the call will be available on the company's website.
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
Prothena Corporation plc announced it will report its fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the U.S. financial markets close. This will be followed by a live audio conference call at 4:30 PM ET, accessible via the company's website and dial-in numbers. A replay will be available for 90 days on the website and via dial-in until February 26, 2026.
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
Prothena Corporation plc (NASDAQ:PRTA) announced it will report its fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of U.S. financial markets. This announcement will be followed by a live audio conference call at 4:30 PM ET. The company, a late-stage clinical biotechnology firm, specializes in protein dysregulation expertise for neurodegenerative and rare peripheral amyloid diseases.
